Immuno-Oncology Xchange Europe
- Should Immunological anti-cancer therapies precede non immunological interventions?
- Are there absolute no go areas for certain sequences due to feasibility?
- We are able to test therapies reasonably well. Are we really able to identify the right patients for each sequence ?
- If only sequences in select order lead to true OS advantages, how do we handle development, approval and reimbursement of each phase?
Head of Medical Affairs, Oncology,
Michael initially pursued a career in General, Cardiovascular and Surgical Oncology in Germany and the UK, gaining an MD and an FRCS. He joined pharmaceutical industry 25 years ago and has since been in clinical development, project leadership, and commercial and medical affairs roles at country, regional and global level. To date, Michael leads the Medical Affairs Team of Novartis Oncology, Region Europe.
Throughout his industry career, Michael mainly covered specialty care areas, e.g. Oncology and Immunology. He qualified as a Pharmaceutical Physician and as an MBA. Research interests and publications are in Oncology and Immunology, advanced analytics/AI as well as in general aspects concerning Medical Affairs and Medicine Development in the Industry.
- Current approaches/platforms for biomarker screening, identification and validation moving from translational research into clinical validation
- What are the major barriers to moving biomarker research initiatives into a clinical application (eg. technology limit, biological relevance, validation)?
- Among available platforms, what are the strengths and weaknesses of current technologies in deploying strategies to develop biomarkers to ultimately aid in more intelligently advancing clinical trials?
Senior Field Application Scientist
Angela Vasaturo is a Senior Field Application Scientist at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. From 2010-2015 Angela was a postdoctoral researcher in the field of Tumor Immunology at the NCMLS in Nijmegen, NL, and was the recipient of an EMBO short-term fellowship, amongst others. In 2012, Angela was among the first postdocs in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, multispectral digital pathology, and tissue imaging.
- Who will benefit from checkpoint inhibition monotherapy? Who needs immune stimulation in order to benefit from checkpoint inhibition?
- Why can early stage cancer patients elicit an anti-tumour response much easier than more advanced patients? What are the necessary clues from basic immuno-biology needed for drug and CDx development?
- How to deal with immune biomarker dynamics? What are disease-specific differences in immune biomarker testing?
Medical Affairs Biomarker Leader, gRED Oncology Biomarker Development Group
Regula has 12 years of experience in Pharma Development at Roche and is leading the Medical Affairs Biomarker Team in Basel since 2016. She is responsible for the implementation of the biomarker and CDx strategy specifically in the breast and GYN cancer disease area. In her work, she is bringing global biomarker leaders and biomarker scientists from Affiliates together and is collaborating with academic leaders.
Regula has obtained her Ph.D. from ETH Zurich (Switzerland) where she worked in the Laboratory for Transplantation Immunology. She joined Roche in 2008.
2:05pm – 2:35pm
2:35pm – 3:05pm
4:15pm – 5:15pm
Closing Keynote & Address